BeyondSpring

1D
1W
1M
3M
YTD
1Y
5Y
ALL

Why Robinhood?

Robinhood gives you the tools you need to put your money in motion. You can buy or sell BeyondSpring and other ETFs, options, and stocks.

About BYSI

BeyondSpring, Inc. engages in the development and commercialization of immuno-oncology cancer therapies. It operates through the Plinabulin Pipeline and TPD Platform segments. 

CEO
Lan Huang
CEOLan Huang
Employees
40
Employees40
Headquarters
Florham Park, New Jersey
HeadquartersFlorham Park, New Jersey
Founded
2010
Founded2010
Employees
40
Employees40

BYSI Key Statistics

Market cap
76.49M
Market cap76.49M
Price-Earnings ratio
-4.97
Price-Earnings ratio-4.97
Dividend yield
Dividend yield
Average volume
1.29M
Average volume1.29M
High today
$1.93
High today$1.93
Low today
$1.85
Low today$1.85
Open price
$1.92
Open price$1.92
Volume
95.97K
Volume95.97K
52 Week high
$3.44
52 Week high$3.44
52 Week low
$0.98
52 Week low$0.98

Stock Snapshot

BeyondSpring(BYSI) stock is priced at $1.87, giving the company a market capitalization of 76.49M. It carries a P/E multiple of -4.97.

On 2025-12-17, BeyondSpring(BYSI) stock traded between a low of $1.85 and a high of $1.93. Shares are currently priced at $1.87, which is +1.1% above the low and -3.1% below the high.

The BeyondSpring(BYSI)'s current trading volume is 95.97K, compared to an average daily volume of 1.29M.

In the last year, BeyondSpring(BYSI) shares hit a 52-week high of $3.44 and a 52-week low of $0.98.

In the last year, BeyondSpring(BYSI) shares hit a 52-week high of $3.44 and a 52-week low of $0.98.

BYSI News

TipRanks 2d
Beyondspring Delays Second Closings of Share Sale

Claim 50% Off TipRanks Premium and Invest with Confidence Unlock hedge-fund level data and powerful investing tools designed to help you make smarter, sharper...

TipRanks 6d
BeyondSpring presents Phase 3 DUBLIN-3 data at ESMO Asia Congress

BeyondSpring (BYSI) announced results from the Asian subset of its global Phase 3 DUBLIN-3 trial evaluating Plinabulin plus docetaxel compared to docetaxel alon...

TipRanks 7d
BeyondSpring’s Plinabulin combination shows survival benefit in NSCLC

BeyondSpring (BYSI) announced new post-hoc analyses from its global Phase 3 DUBLIN-3 Study showing that Plinabulin plus docetaxel provides clinically meaningful...

People also own

Based on the portfolios of people who own BYSI. This list is generated using Robinhood data, and it’s not a recommendation.
All investments involve risks, including the loss of principal. Securities trading offered through Robinhood Financial LLC, Member SIPC and a registered broker-dealer.